Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02454660 · ClinicalTrials.gov registry record · NA
Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages
A NA study of Medication Non Adherence, sponsored by University of Michigan.
- Completed
- Registry status
- NA
- Development phase
- 49
- Enrollment target
- 2
- Study locations
NCT02454660: Completed NA study of Medication Non Adherence, sponsored by University of Michigan.
NCT02454660 is a NA study of Medication Non Adherence that has completed, run by University of Michigan. The registered enrollment target is 49 participants, below the 92-participant average among 4 other Medication Non Adherence trials with a reported enrollment target (47% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02454660, a NA study of Medication Non Adherence, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- NA
- Development phase
- 49 participants
- Enrollment target
- 2
- Study locations
Study Summary
Uncontrolled hypertension is a major cause of morbidity and mortality and many patients fail to take their antihypertensive medication as prescribed. The investigators propose to use artificial intelligence (AI) to allow short message service (SMS or text messages) interventions to adapt to patients' adherence needs and substantially improve medication taking. The aims of the study are to: (1) develop AI methods for adaptive decision-making in human-centered environments and demonstrate the feasibility of the resulting AI-enhanced SMS medication adherence intervention, (2) demonstrate that the intervention can "learn" by adapting the SMS message stream according to patients' medication taking over time, and (3) examine potential intervention impact as measured by improvements in medication adherence and systolic blood pressures. The investigators will recruit 100 patients with uncontrolled hypertension and antihypertensive medication non-adherence. Adherence and other covariates will be measured via surveys at baseline, 3- and 6 months; blood pressures will be measured at baseline and 6 months. Participants will be given an electronic pill-bottle adherence monitor. Participants will receive SMS messages designed to motivate antihypertensive medication adherence. Message content and frequency will adapt automatically using AI algorithms designed to automatically optimize expected pill bottle opening. For Aim 1, the first 25 patients will be enrolled to develop and test alternative RL algorithms and fine-tune the system parameters. For Aim 2, the investigators will examine changes in the probability distribution over message-types and compare that distribution with patients' reasons for non-adherence reported at baseline. For Aim 3, the investigators will examine changes in self-reported medication non-adherence and blood pressure and automatically-reported pill bottle openings. This pilot study will establish the feasibility and potential impact of this novel approac
Primary Outcome
A measure of Proportion Days Covered (PDC) and is assessed administrative insurance records
Conditions Studied
Interventions
- BEHAVIORAL SMS (Text messages)
Study Locations (2)
Michigan
- University of Michigan College of Pharmacy - Ann Arbor
- Spectrum Health - Grand Rapids
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-11-04 |
| Phase | NA |
What the finished NCT02454660 record still lists
NCT02454660 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 92-participant average among 4 other Medication Non Adherence trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Medication Non Adherence appearing as the primary indexed condition, and to 1 intervention - of which SMS (Text messages) is the first listed.
NCT02454660 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT02454660 about?
NCT02454660 is a clinical study titled "Improving Adherence and Outcomes by Artificial Intelligence-Adapted Text Messages". Uncontrolled hypertension is a major cause of morbidity and mortality and many patients fail to take their antihypertensive medication as prescribed. The investigators propose to use artificial intelligence (AI) to allow short message service (SMS or text messages) interventions to adapt to patients...
What is the current status of trial NCT02454660?
This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2015-05. Estimated completion is 2016-11-04.
What conditions does trial NCT02454660 study?
This clinical trial studies the following conditions: Medication Non Adherence.
What interventions are being tested in trial NCT02454660?
The interventions under investigation include: SMS (Text messages) (BEHAVIORAL).
Who is sponsoring clinical trial NCT02454660?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02454660 being conducted?
This trial has 2 study locations across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Medication Non Adherence
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Mobile Video Directly Observed Therapy (DOT) for Immunosuppression Medication Adherence in Adolescent Heart Transplant Recipients
RECRUITING · NA
-
Tailored Medication Management Intervention
COMPLETED · NA
-
A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness
COMPLETED · NA
-
Patient Centered Health Technology Medication Adherence Program for African American Hypertensives
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia